Renaissance Technologies LLC raised its position in Teladoc Health, Inc. (NYSE:TDOC – Free Report) by 1.3% during the first quarter, HoldingsChannel.com reports. The firm owned 8,085,542 shares of the health services provider’s stock after purchasing an additional 107,400 shares during the period. Renaissance Technologies LLC’s holdings in Teladoc Health were worth $44,066,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP grew its stake in shares of Teladoc Health by 8.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 7,494,255 shares of the health services provider’s stock valued at $52,459,000 after buying an additional 605,061 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Teladoc Health by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 4,188,313 shares of the health services provider’s stock worth $29,324,000 after acquiring an additional 18,394 shares during the last quarter. Jupiter Asset Management Ltd. lifted its stake in shares of Teladoc Health by 293.9% during the 4th quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock worth $27,021,000 after acquiring an additional 2,880,008 shares during the last quarter. Pale Fire Capital SE boosted its holdings in Teladoc Health by 74.8% during the 1st quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock valued at $18,522,000 after acquiring an additional 1,454,288 shares during the period. Finally, Nuveen LLC grew its position in Teladoc Health by 38.7% in the 4th quarter. Nuveen LLC now owns 2,659,662 shares of the health services provider’s stock valued at $18,618,000 after acquiring an additional 742,240 shares during the last quarter. Institutional investors own 76.82% of the company’s stock.
Teladoc Health Stock Performance
Shares of TDOC stock opened at $8.89 on Tuesday. The firm has a market cap of $1.61 billion, a price-to-earnings ratio of -9.17 and a beta of 2.10. Teladoc Health, Inc. has a 52-week low of $4.40 and a 52-week high of $9.89. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.75. The company’s 50 day moving average is $8.10 and its 200 day moving average is $6.52.
Wall Street Analyst Weigh In
A number of research firms have weighed in on TDOC. Canaccord Genuity Group increased their target price on Teladoc Health from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Citigroup boosted their target price on shares of Teladoc Health from $6.00 to $7.00 and gave the company a “neutral” rating in a research note on Tuesday, May 5th. Weiss Ratings upgraded shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Finally, Bank of America raised their price target on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $7.57.
Check Out Our Latest Stock Report on Teladoc Health
Insider Buying and Selling
In other Teladoc Health news, insider Adam C. Vandervoort sold 7,906 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $60,322.78. Following the completion of the sale, the insider directly owned 110,261 shares of the company’s stock, valued at approximately $841,291.43. This represents a 6.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $145,977.16. Following the completion of the sale, the chief executive officer owned 389,894 shares in the company, valued at $2,974,891.22. This represents a 4.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 39,195 shares of company stock worth $299,058 in the last three months. 0.70% of the stock is owned by company insiders.
Teladoc Health Profile
Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.
Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.
Read More
- Five stocks we like better than Teladoc Health
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health, Inc. (NYSE:TDOC – Free Report).
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.
